266 related articles for article (PubMed ID: 7655028)
1. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo.
Shalev O; Repka T; Goldfarb A; Grinberg L; Abrahamov A; Olivieri NF; Rachmilewitz EA; Hebbel RP
Blood; 1995 Sep; 86(5):2008-13. PubMed ID: 7655028
[TBL] [Abstract][Full Text] [Related]
2. Nonrandom association of free iron with membranes of sickle and beta-thalassemic erythrocytes.
Repka T; Shalev O; Reddy R; Yuan J; Abrahamov A; Rachmilewitz EA; Low PS; Hebbel RP
Blood; 1993 Nov; 82(10):3204-10. PubMed ID: 8219209
[TBL] [Abstract][Full Text] [Related]
3. Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia.
Browne PV; Shalev O; Kuypers FA; Brugnara C; Solovey A; Mohandas N; Schrier SL; Hebbel RP
J Clin Invest; 1997 Sep; 100(6):1459-64. PubMed ID: 9294111
[TBL] [Abstract][Full Text] [Related]
4. The chelation of nonheme iron within sickle erythrocytes by the hydroxypyridinone chelator CP094.
Hartley A; Rice-Evans C
Arch Biochem Biophys; 1992 Sep; 297(2):377-82. PubMed ID: 1497355
[TBL] [Abstract][Full Text] [Related]
5. Transport of 14C-deferiprone in normal, thalassaemic and sickle red blood cells.
Shalev O; Hileti D; Nortey P; Hebbel RP; Hoffbrand VA
Br J Haematol; 1999 Jun; 105(4):1081-3. PubMed ID: 10554823
[TBL] [Abstract][Full Text] [Related]
6. L1 effects on reactive oxygen (ROS) and nitrogen species (RNS) release, hemoglobin oxidation, low molecular weight antioxidants, and antioxidant enzyme activities in red and white blood cells of thalassemic patients.
Korkina L; De Luca C; Deeva I; Perrotta S; Nobili B; Passi S; Puddu P
Transfus Sci; 2000 Dec; 23(3):253-4. PubMed ID: 11099907
[No Abstract] [Full Text] [Related]
7. Detection, characterization, and bioavailability of membrane-associated iron in the intact sickle red cell.
Sugihara T; Repka T; Hebbel RP
J Clin Invest; 1992 Dec; 90(6):2327-32. PubMed ID: 1469090
[TBL] [Abstract][Full Text] [Related]
8. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
Collins AF; Fassos FF; Stobie S; Lewis N; Shaw D; Fry M; Templeton DM; McClelland RA; Koren G; Olivieri NF
Blood; 1994 Apr; 83(8):2329-33. PubMed ID: 8161801
[TBL] [Abstract][Full Text] [Related]
9. Effect of transfusion on lipid peroxidation products in the plasma of thalassemic patients.
Sher GD; Bartfay WJ; Liu PP; Lehotay DC
Transfusion; 1999 Mar; 39(3):333-4. PubMed ID: 10204599
[No Abstract] [Full Text] [Related]
10. Nonheme iron in sickle erythrocyte membranes: association with phospholipids and potential role in lipid peroxidation.
Kuross SA; Hebbel RP
Blood; 1988 Oct; 72(4):1278-85. PubMed ID: 3167208
[TBL] [Abstract][Full Text] [Related]
11. Free radical formation and oxyhemoglobin oxidation in beta-thalassemic red blood cells in the presence of prooxidants: effects of the free radical scavenger rutin and oral chelator L1.
Afanas'ev IB; Afanas'ev II; Deeva IB; Korkina LG
Transfus Sci; 2000 Dec; 23(3):237-8. PubMed ID: 11099899
[No Abstract] [Full Text] [Related]
12. Extremely high avidity association of Fe(III) with the sickle red cell membrane.
Shalev O; Hebbel RP
Blood; 1996 Jul; 88(1):349-52. PubMed ID: 8704194
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents.
Repka T; Hebbel RP
Blood; 1991 Nov; 78(10):2753-8. PubMed ID: 1668610
[TBL] [Abstract][Full Text] [Related]
14. Deferiprone therapy in homozygous human beta-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity.
de Franceschi L; Shalev O; Piga A; Collell M; Olivieri O; Corrocher R; Hebbel RP; Brugnara C
J Lab Clin Med; 1999 Jan; 133(1):64-9. PubMed ID: 10385483
[TBL] [Abstract][Full Text] [Related]
15. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator.
Pootrakul P; Breuer W; Sametband M; Sirankapracha P; Hershko C; Cabantchik ZI
Blood; 2004 Sep; 104(5):1504-10. PubMed ID: 15155464
[TBL] [Abstract][Full Text] [Related]
16. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
[TBL] [Abstract][Full Text] [Related]
17. Iron distribution and histopathological study of the effects of deferoxamine and deferiprone in the kidneys of iron overloaded β-thalassemic mice.
Yatmark P; Morales NP; Chaisri U; Wichaiyo S; Hemstapat W; Srichairatanakool S; Svasti S; Fucharoen S
Exp Toxicol Pathol; 2016 Sep; 68(8):427-34. PubMed ID: 27402198
[TBL] [Abstract][Full Text] [Related]
18. Alternative treatment paradigm for thalassemia using iron chelators.
Szuber N; Buss JL; Soe-Lin S; Felfly H; Trudel M; Ponka P
Exp Hematol; 2008 Jul; 36(7):773-85. PubMed ID: 18456387
[TBL] [Abstract][Full Text] [Related]
19. Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
Calvaruso G; Vitrano A; Di Maggio R; Ballas S; Steinberg MH; Rigano P; Sacco M; Telfer P; Renda D; Barone R; Maggio A;
Blood Cells Mol Dis; 2014 Dec; 53(4):265-71. PubMed ID: 24814618
[TBL] [Abstract][Full Text] [Related]
20. Iron and atherosclerosis: inhibition by the iron chelator deferiprone (L1).
Matthews AJ; Vercellotti GM; Menchaca HJ; Bloch PH; Michalek VN; Marker PH; Murar J; Buchwald H
J Surg Res; 1997 Nov; 73(1):35-40. PubMed ID: 9441790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
